This is a correction to: Yusuke Chihara, Takayuki Takeda, Yasuhiro Goto, Yoichi Nakamura, Yuko Tsuchiya-Kawano, Akira Nakao, Keisuke Onoi, Makoto Hibino, Minoru Fukuda, Ryoichi Honda, Takahiro Yamada, Ryusuke Taniguchi, Sinjiro Sakamoto, Koji Date, Seiji Nagashima, Shigeru Tanzawa, Koichi Minato, Koichi Nakatani, Miiru Izumi, Takayuki Shimose, Junji Kishimoto, Junji Uchino, Koichi Takayama, A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study, The Oncologist, Volume 27, Issue 11, November 2022, Pages 903–e834, https://doi.org/10.1093/oncolo/oyac193
The published article states that:
The overall incidence of AEs in the present study (95%) was similar to that in the FLAURA study and the Japanese subset of the FLAURA study (98% vs. 100%, respectively), while that of AEs of grade 3 or higher in the present study (35%) was similar to that in the FLAURA study (34%) and lower than that in the FLAURA Japanese subset (47.7%), with the incidence of the most common AEs of grade 3 or higher being 5%. All toxicities are listed in Table 2.
The authors wish to clarify that 95% is the percentage for all adverse events excluding abnormal laboratory values, and it is desirable to correct it to 100%--hence Table 2 gives a value of 100% for hypoalbuminemia.
Furthermore, the percentage of G3 or higher adverse events, published as 35%, should read as to 37.5%, accordingly.
These details have been corrected only in this correction notice to preserve the published version of record.